Tags

Type your tag names separated by a space and hit enter

Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis.
Respir Res. 2015 Sep 29; 16:120.RR

Abstract

BACKGROUND

Matrix metalloproteinases (MMPs) are believed to be involved in the pathogenesis of idiopathic pulmonary fibrosis (IPF), and MMP-7 has been described as a useful biomarker for IPF. However, little is known regarding the significance of MMP-10 as a biomarker for IPF.

METHODS

This observational cohort study included 57 patients with IPF. Serum MMPs were comprehensively measured in all patients, and the relationships between these markers and both disease severity and prognosis were evaluated. Bronchoalveolar lavage fluid (BALF) MMP-7 and -10 levels were measured in 19 patients to investigate the correlation between these markers and their corresponding serum values. Immunohistochemical staining for MMP-10 was also performed in IPF lung tissue.

RESULTS

Serum MMP-7 and -10 levels correlated significantly with both the percentage of predicted forced vital capacity (ρ = -0.31, p = 0.02 and ρ = -0.34, p < 0.01, respectively) and the percentage of predicted diffusing capacity of the lung for carbon monoxide (ρ = -0.32, p = 0.02 and ρ = -0.43, p < 0.01, respectively). BALF MMP-7 and -10 levels correlated with their corresponding serum concentrations. Only serum MMP-10 predicted clinical deterioration within 6 months and overall survival. In IPF lungs, the expression of MMP-10 was enhanced and localized to the alveolar epithelial cells, macrophages, and peripheral bronchiolar epithelial cells.

CONCLUSIONS

MMP-10 may be a novel biomarker reflecting both disease severity and prognosis in patients with IPF.

Authors+Show Affiliations

Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. asokai@kuhp.kyoto-u.ac.jp.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. hanta@kuhp.kyoto-u.ac.jp.Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. tanizawa@kuhp.kyoto-u.ac.jp.Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. ogato@kuhp.kyoto-u.ac.jp.Louis Pasteur Center for Medical Research, Kyoto, Japan. kazukouno@louis-pasteur.or.jp.Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. tsuruyam@kuhp.kyoto-u.ac.jp.Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. tkubo@kuhp.kyoto-u.ac.jp.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. koikezoe@kuhp.kyoto-u.ac.jp.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. yosnaka@kuhp.kyoto-u.ac.jp.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. kaztani@kuhp.kyoto-u.ac.jp.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. smuro@kuhp.kyoto-u.ac.jp.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. t_hirai@kuhp.kyoto-u.ac.jp.Kyoto Central Clinic/Clinical Research Center, Sakyo-ku, Kyoto, Japan. nagai@chuo-c.jp.Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. chink@kuhp.kyoto-u.ac.jp.Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan. mishima@kuhp.kyoto-u.ac.jp.

Pub Type(s)

Journal Article
Observational Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26415518

Citation

Sokai, Akihiko, et al. "Matrix Metalloproteinase-10: a Novel Biomarker for Idiopathic Pulmonary Fibrosis." Respiratory Research, vol. 16, 2015, p. 120.
Sokai A, Handa T, Tanizawa K, et al. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respir Res. 2015;16:120.
Sokai, A., Handa, T., Tanizawa, K., Oga, T., Uno, K., Tsuruyama, T., Kubo, T., Ikezoe, K., Nakatsuka, Y., Tanimura, K., Muro, S., Hirai, T., Nagai, S., Chin, K., & Mishima, M. (2015). Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. Respiratory Research, 16, 120. https://doi.org/10.1186/s12931-015-0280-9
Sokai A, et al. Matrix Metalloproteinase-10: a Novel Biomarker for Idiopathic Pulmonary Fibrosis. Respir Res. 2015 Sep 29;16:120. PubMed PMID: 26415518.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis. AU - Sokai,Akihiko, AU - Handa,Tomohiro, AU - Tanizawa,Kiminobu, AU - Oga,Toru, AU - Uno,Kazuko, AU - Tsuruyama,Tatsuaki, AU - Kubo,Takeshi, AU - Ikezoe,Kohei, AU - Nakatsuka,Yoshinari, AU - Tanimura,Kazuya, AU - Muro,Shigeo, AU - Hirai,Toyohiro, AU - Nagai,Sonoko, AU - Chin,Kazuo, AU - Mishima,Michiaki, Y1 - 2015/09/29/ PY - 2015/05/07/received PY - 2015/09/20/accepted PY - 2015/9/30/entrez PY - 2015/9/30/pubmed PY - 2016/7/12/medline SP - 120 EP - 120 JF - Respiratory research JO - Respir Res VL - 16 N2 - BACKGROUND: Matrix metalloproteinases (MMPs) are believed to be involved in the pathogenesis of idiopathic pulmonary fibrosis (IPF), and MMP-7 has been described as a useful biomarker for IPF. However, little is known regarding the significance of MMP-10 as a biomarker for IPF. METHODS: This observational cohort study included 57 patients with IPF. Serum MMPs were comprehensively measured in all patients, and the relationships between these markers and both disease severity and prognosis were evaluated. Bronchoalveolar lavage fluid (BALF) MMP-7 and -10 levels were measured in 19 patients to investigate the correlation between these markers and their corresponding serum values. Immunohistochemical staining for MMP-10 was also performed in IPF lung tissue. RESULTS: Serum MMP-7 and -10 levels correlated significantly with both the percentage of predicted forced vital capacity (ρ = -0.31, p = 0.02 and ρ = -0.34, p < 0.01, respectively) and the percentage of predicted diffusing capacity of the lung for carbon monoxide (ρ = -0.32, p = 0.02 and ρ = -0.43, p < 0.01, respectively). BALF MMP-7 and -10 levels correlated with their corresponding serum concentrations. Only serum MMP-10 predicted clinical deterioration within 6 months and overall survival. In IPF lungs, the expression of MMP-10 was enhanced and localized to the alveolar epithelial cells, macrophages, and peripheral bronchiolar epithelial cells. CONCLUSIONS: MMP-10 may be a novel biomarker reflecting both disease severity and prognosis in patients with IPF. SN - 1465-993X UR - https://www.unboundmedicine.com/medline/citation/26415518/Matrix_metalloproteinase_10:_a_novel_biomarker_for_idiopathic_pulmonary_fibrosis_ L2 - https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-015-0280-9 DB - PRIME DP - Unbound Medicine ER -